Godavari Biorefineries Limited has informed the Exchange that the China National Intellectual Property Administration (CNIPA) has granted our patent entitled "5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 4.6 pts more than its Fast Moving Consumer Goods peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Godavari Biorefineries has been granted a patent by China's patent office (CNIPA) for a compound called 5-Hydroxy-1,4-naphthalenedione, which has shown strong inhibitory effects on cancer and cancer stem cells in laboratory (in vitro) studies. The compound demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. The patent covers a novel class of compounds with potential applications in oncology treatment. This is an intellectual property milestone in a key market (China) and strengthens the company's patent portfolio, though the work is still at a pre-clinical stage.
Positive for the company's long-term IP portfolio and potential future pharma/oncology opportunities, but no immediate revenue or commercial impact as the compound is still in pre-clinical (in vitro) stage and not yet generating sales.